The D3 dopamine receptor and substance dependence

Journal of Addictive Diseases

Volumn 20, Issue 3, 2001, Pages 19-32

  Richtand, Neil M ^a,b   Goldsmith, R Jeffrey ^a,b   Nolan, Julie E ^a,b   Berger, S Paul ^a,b  

^a Veteran's Hospital Medical Center   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Behavioral sensitization; Cocaine; Dopamine D3 receptor; Stimulant drugs

Indexed keywords

AMPHETAMINE; CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; RECEPTOR SUBTYPE;

BEHAVIOR; DOPAMINERGIC SYSTEM; LOCOMOTION; MODEL; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; REVIEW; SENSITIZATION; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE-RELATED DISORDERS;

EID: 0035182432     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v20n03_03     Document Type: Article

References (86)

1. Di Chiara G, Imperato A. Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol, and barbiturates: studies with transcerebral dialysis in freely moving rats. Ann NY Acad Sci. 1986; 473: 367-81.
2. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992; 13: 177-84.
3. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991; 16: 223-44.
4. Segal DS, Mandell AJ. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav. 1974; 2: 249-55.
5. Segal DS, Weinberger SB, Cahill J, McCunney SJ. Multiple daily amphetamine administration: behavioral and neurochemical alterations. Science. 1980; 207: 905-7.
6. Strakowski SM, Sax KW. Progressive behavioral response to repeated d-am-phetamine challenge: further evidence for sensitization in humans. Biol Psychiatry. 1998; 44: 1171-7.
7. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sen- sitization theory of addiction. Brain Res Brain Res Rev. 1993; 18: 247-91.
8. Piazza PV, Deminiere JM, Le Moal M, Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science. 1989; 245: 1511-3.
9. Piazza PV, Deminiere JM, Le Moal M, Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 1990; 514: 22-6.
10. Spano PF, Govoni S, Trabucchi M. Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Adv Biochem Psychopharmacol. 1978; 19: 155-65.
11. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev. 1998; 78: 189-225.
12. Bunzow JR, VanTol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 1988; 336: 783-7.
13. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347: 146-51.
14. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev. 1997; 49: 231-52.
15. Schwartz JC, Diaz J, Bordet R, et al. Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Res Brain Res Rev. 1998; 26: 236-42.
16. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuro-psycho-pharmacology. 1999; 20: 60-80.
17. Bouthenet ML, Souil E, Martres MP, et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991; 564: 203-19.
18. Meador-Woodruff JH, Mansour A, Saul J, Watson, SJ. Neuroanatomical Distribution of Dopamine Receptor Messenger RNAs. In: Niznik HB, ed. Dopamine Receptors and Transporters: Pharmacology, Structure, and Function. New York: Marcel Dekker, Inc., 1994; 401-15.
19. Meador-Woodruff JH, Mansour A, Healy DJ, et al. Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology. 1991; 5: 231-42.
20. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990; 250: 1429-32.
21. Gerfen CR, McGinty JF, Young WS. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histo-chemical analysis. J Neurosci. 1991; 11: 1016-31.
22. Le Moine C, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene. Proc Natl Acad Sci USA. 1991; 88: 4205-9.
23. Landwehrmeyer B, Mengod G, Palacios JM. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci. 1993; 5: 145-53.
24. Landwehrmeyer B, Mengod G, Palacios JM. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res. 1993; 18: 187-92.
25. Levant B. Differential distribution of D3 dopamine receptors in the brains of several mammalian species. Brain Res. 1998; 800: 269-74.
26. Levesque D, Diaz J, Pilon C, et al. Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N, N-di-n-propyl- 2-aminotetralin. Proc Natl Acad Sci USA. 1992; 89: 8155-9.
27. Richtand NM, Kelsoe JR, Segal DS, Kuczenski R. Regional quantification of D1, D2, and D3 dopamine receptor mRNA in rat brain using a ribonuclease protection assay. Brain Res Mol Brain Res. 1995; 33: 97-103.
28. Gobert A, Rivet JM, Audinot V, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and “silent” D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther. 1995; 275: 899-913.
29. O’Hara CM, Uhland-Smith A, O’Malley KL, Todd, RD. Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther. 1996; 277: 186-192.
30. Rivet JM, Audinot V, Gobert A, et al. Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol. 1994; 265: 175-7.
31. Tang L, Todd RD, O’Malley KL. Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther. 1994; 270: 475-9.
32. Kling-Petersen T, Ljung E, Svensson K. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect. 1995; 102: 209-20.
33. Svensson K, Carlsson A, Huff RM, et al. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol. 1994; 263: 235-43.
34. Waters N, Lofberg L, Haadsma-Svensson S, et al. Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect. 1994; 98: 39-55.
35. Waters N, Svensson K, Haadsma-Svensson SR, et al. The dopamine D3-recep- tor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect. 1993; 94: 11-19.
36. Koeltzow TE, Xu M, Cooper DC, et al. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J Neurosci. 1998; 18: 2231-38.
37. L’hirondel M, Cheramy A, Godeheu G, et al. Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice. Brain Res. 1998; 792: 253-62.
38. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev. 1997; 25: 192-216.
39. Steketee JD, Sorg BA, Kalivas PW. The role of the nucleus accumbens in sensitization to drugs of abuse. Prog Neuropsychopharmacol Biol Psychiatry. 1992; 16: 237-46.
40. Ridray S, Griffon N, Mignon V, et al. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur J Neurosci. 1998; 10: 1676-86.
41. Diaz J, Levesque D, Griffon N, et al. Opposing roles for dopamine D2 andD3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci. 1994; 6: 1384-7.
42. Glick SD, Lyon RA, Hinds PA, et al. Correlated asymmetries in striatal D1 and D2 binding: relationship to apomorphine-induced rotation. Brain Res. 1988; 455: 43-8.
43. Sibley DR, Monsma FJJ, Shen Y. Molecular neurobiology of dopaminergic receptors. Int Rev Neurobiol. 1993; 35: 391-415.
44. Walters JR, Bergstrom DA, Carlson JH, et al. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 1987; 236: 719-22.
45. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA. 1996; 93: 1945-9.
46. Xu M, Koeltzow TE, Santiago GT, et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997; 19: 837-48.
47. Ahlenius S, Salmi P. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treatedrat. Eur J Pharmacol. 1994; 260: 177-81.
48. Daly SA, Waddington JL. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other “D-2-like” agonists. Neuropharmacology. 1993; 32: 509-10.
49. Depoortere R, Perrault G, Sanger DJ. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine Psychopharmacology (Berl). 1996; 124: 231-40.
50. Gilbert DB, Cooper SJ. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects. Pharmacol Biochem Behav. 1995; 52: 275-80.
51. Kagaya T, Yonaga M, Furuya Y, et al. Dopamine D3 agonists disrupt social behavior in rats. Brain Res. 1996; 721: 229-32.
52. Khroyan TV, Baker DA, Neisewander JL. Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl). 1995; 122: 351-7.
53. Pugsley TA, Davis MD, Akunne HC, et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. JPharmacol Exp Ther. 1995; 275: 1355-66.
54. Starr MS, Starr BS. Motor actions of 7-OH-DPAT in normal and reser- pine-treated mice suggest involvement of both dopamine D2 and D3 receptors. Eur J Pharmacol. 1995; 277: 151-8.
55. Svensson K, Carlsson A, Waters N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect. 1994; 95: 71-4.
56. Clifford JJ, Waddington, JL. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach. Psychopharmacology (Berl). 1998; 136: 284-90.
57. Corbin AE, Pugsley TA, Akunne HC, et al. Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol Biochem Behav. 1998; 59: 487-93.
58. Sautel F, Griffon N, Sokoloff P, et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995; 275: 1239-46.
59. Svensson K, Johansson AM, Magnusson T, Carlsson A. (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol. 1986; 334: 234-45.
60. Piercey MF, Lum JT, Hoffmann WE, et al. Antagonism of cocaine’s pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232. Brain Res. 1992; 588: 217-22.
61. Flores G, Barbeau D, Quirion R, et al. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci. 1996; 16: 2020-6.
62. Sigala S, Missale C, Spano P. Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol. 1997; 336: 107-12.
63. Sokoloff P, Martres MP, Giros B, et al. The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol. 1992; 43: 659-66.
64. Ross SB. Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem. 1991; 56: 22-9.
65. Kalivas PW, Duffy P. Time course of extracellular dopamine and behavioral sensitization to cocaine. I. Dopamine axon terminals. J Neurosci. 1993; 13: 266-75.
66. Parsons LH, Justice JBJ. Extracellular concentration and in vivo recovery of dopamine in the nucleus accumbens using microdialysis. J Neurochem. 1992; 58: 212-8.
67. Kawagoe KT, Garris PA, Wiedemann DJ, Wightman RM. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum. Neuroscience. 1992; 51: 55-64.
68. Garris PA, Ciolkowski EL, Pastore P, Wightman RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci. 1994; 14: 6084-93.
69. Jones SR, Lee TH, Wightman RM, Ellinwood EH. Effects of intermittent and continuous cocaine administration on dopamine release and uptake regulation in the striatum: in vitro voltammetric assessment. Psychopharmacology (Berl). 1996; 126: 331-8.
70. Jones SR, O’Dell SJ, Marshall JF, Wightman RM. Functional and anatomical evidence for different dopamine dynamics in the core and shell of the nucleus accumbens in slices of rat brain. Synapse. 1996; 23: 224-31.
71. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U. In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem. 1983; 41: 1769-73.
72. Ramsay DS, Woods SC. Biological consequences of drug administration: implications for acute and chronic tolerance. Psychol Rev. 1997; 104: 170-93.
73. Richtand NM, Logue AD, Welge JA, et al. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 2000; 867: 239-42.
74. Hondo H, Spitzer RH, Grinius B, Richtand NM. Quantification of dopamine D3 receptor mRNA level associated with the development of amphetamine-induced behavioral sensitization in the rat brain. Neurosci Lett. 1999; 264: 69-72.
75. Wallace DR, Mactutus CF, Booze RM. Repeated intravenous cocaine administration: locomotor activity and dopamine D2/D3 receptors. Synapse. 1996; 23: 152-63.
76. Deminiere JM, Piazza PV, Guegan G, et al. Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers. Brain Res. 1992; 586: 135-9.
77. Henry C, Guegant G, Cador M, et al. Prenatal stress in rats facilitates amphetamine-induced sensitization and induces long-lasting changes in dopamine receptors in the nucleus accumbens. Brain Res. 1995; 685: 179-86.
78. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 1993; 9: 67-75.
79. Mattingly BA, Fields SE, Langfels MS, et al. Repeated 7-OH-DPAT treatments: behavioral sensitization, dopamine synthesis and subsequent sensitivity to apomorphine and cocaine. Psychopharmacology (Berl). 1996; 125: 33-42.
80. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA. 1997; 94: 3363-7.
81. Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. 1996; 16: 6100-6.
82. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237: 1219-23.
83. Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science. 1993; 260: 1814-6.
84. Caine SB, Koob GF, Parsons LH, et al. D3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport. 1997; 87: 2373-7.
85. Parsons LH, Caine SB, Sokoloff P, et al. Neurochemical evidence that post- synaptic nucleus accumbens D3 receptor stimulation enhances cocaine reinforcement. J Neurochem. 1996; 67: 1078-89.
86. Pilla M, Perachon S, Sautel F, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 1999; 400: 371-5.